Take control of von Willebrand disease

wilate® wilate® is a VWF/FVIII complex indicated in children and adults with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes in children 6 years of age and older and adults with VWD¹⁻³

Quick links

wilate® is a high-purity plasma-derived von Willebrand factor and coagulation factor VIII (VWF/FVIII) concentrate

wilate® was developed specifically for people with von Willebrand disease (VWD), and contains VWF and FVIII in a physiological 1:1 activity ratio, which may facilitate simple dosing and monitoring even when repeated dosing is needed.4, 5

The purification process includes two virus inactivation steps in order to help ensure a high-purity product free of viral contamination.4

Over 15 years of clinical and real-life experience have proven the efficacy and tolerability of wilate® in people with all types of von Willebrand disease for surgery, on-demand treatment and prophylaxis.1-3

*Based on von Willebrand factor and factor VIII activity levels. FVIII, coagulation factor VIII; VWF, von Willebrand factor.

wilate® is indicated in children age 6 and older and adults with von Willebrand disease for:
• On-demand treatment and control of bleeding episodes
• Perioperative management of bleeding
• Routine prophylaxis to reduce the frequency of bleeding episodes6

Physiological 1:1 ratio of VWF and FVIII in wilate®

One of the functions of VWF is to bind to and protect FVIII from proteolytic degradation.4

As a result, people with von Willebrand disease may have low levels of both VWF and FVIII, both of which need to be corrected in order to restore normal haemostasis.4

wilate® contains VWF and FVIII in a balanced 1:1 ratio*, which is similar to the activity ratio of VWF and FVIII in the plasma of healthy individuals.4

*Based on von Willebrand factor and factor VIII activity levels.

The balanced ratio of VWF and FVIII* may simplify dosing and monitoring of wilate®2

*Based on von Willebrand factor and factor VIII activity levels.

Manufacturing of wilate®

wilate® is a high-purity, human VWF/FVIII concentrate

wilate® is made from pooled human plasma that has been collected in GMP-compliant donation centers.9

FVIII, factor VIII; GMP, good manufacturing practice; VWF, von Willebrand factor.

All individual plasma samples undergo extensive testing for viruses, including for HIV, hepatitis A, B and C and parvovirus B199, 10

FVIII, factor VIII; HIV, human immunodeficiency virus; von Willebrand factor.

wilate® is purified through a series of carefully controlled processing steps, all designed to minimise impurities and ensure viral safety4

Two chromatographic steps ensure high purity and remove non-essential proteins4

Viral safety is achieved by two complementary virus inactivation steps4

Manufacturing of wilate®

Double virus inactivation process

HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus.

Manufacturing of wilate®

wilate® is a high-purity, human VWF/FVIII concentrate

The manufacturing process of wilate® preserves the structure and multimer distribution of VWF seen in the plasma of healthy individuals4

Figure adapted from Windyga et al. 2011
SHP, standard human plasma

References

  1. Srivastava A et al. Haemophilia 2017; 23:264-72.
  2. Windyga J and von Depka-Prondzinski M. Thromb Haemost 2011; 105:1072-9.
  3. Berntorp E and Windyga J. Haemophilia 2009; 15:122-30.
  4. Stadler M et al. Biologicals 2006; 34:281-8.
  5. Kessler CM et al. Thromb Haemost 2011; 106:279-88.
  6. wilate® US PI, updated December 2023.
  7. Sholzberg M et al. TH Open 2021; 5:e264-72.
  8. Octapharma AG, data on file.
  9. octapharma.com/products/quality-and-safety; last accessed July 2021.
  10. octapharma.com/products/production-process; last accessed July 2021.
  11. Biesert L and Suhartano H. Vox Sang 1998; 74(Suppl.1):207-12.
  12. Teitel JM. Ann Med 2000; 32:485-92.